Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis

In collaboration with the North American Consortium for Histiocytosis (NACHO), Melissa Hines and Kim Nichols are running a clinical trial investigating the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for children with newly diagnosed or relapsed/refractory HLH. The protocol is now open at 10 participating sites, including:

  • St. Jude Children’s Research Hospital – Memphis, TN
  • Children’s Hospital of Philadelphia – Philadelphia, PA
  • UCSF Benoiff Children’s Hospital – San Francisco, CA
  • Children’s Hospital of Orange County – Orange , CA
  • Phoenix Children’s Hospital – Phoenix, AZ
  • Atrium Health Levine Children’s Hospital – Charlotte, NC
  • Children’s National Medical Center – Washington, DC
  • Children’s Wisconsin – Milwaukee, WI
  • Cohen Children’s Medical Center – New Hyde Park, NY
  • Johns Hopkins – Baltimore, MD

You can find more information about the study on the attached flyer and at: HLHRUXO clinical trial or at:


We are excited to finally have this study open and are willing to address any questions that you or your colleagues might have. Please contact us at:


Please feel free to refer your patients to St. Jude for or to any of the above centers for potential enrollment.